Statistical analysis
MIBC
PATHOLOGY
Previous studies have shown that patients with MIBC who underwent neoadjuvant GC had a pCR rate of approximately 25%.All eligible patients who received at least one dose of camrelizumab and underwent cystectomy with post‐operative pathologic assessment was included in the efficacy analysis. The pathologic response will be evaluated by a central pathology committee. Safety analysis will include all eligible patients who received at least one dose of camrelizumab.Statistical analyses were conducted using SAS 9.4 and R 3.6.0, and a significance level of 